You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 145 No. 7, July 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Neutropenia in an Extremely Premature Infant Treated With Recombinant Human Granulocyte Colony-Stimulating Factor

Robert L. Roberts, MD, PhD; Cynthia M. Szelc, MD; Steven M. Scates, MD; Maria T. Boyd, RN, MN; Ken M. Soderstrom; Mark W. Davis, MS; John A. Glaspy, MD

Am J Dis Child. 1991;145(7):804-807.


Abstract

Neutropenia in the newborn is often associated with sepsis, maternal hypertension, or prematurity. We describe a 654-g infant born at 30 weeks' gestation by cesarean section due to severe maternal hypertension. His course was complicated by five episodes of sepsis, including three with group B streptococcus. The results of hematologic and immunologic studies were normal except that absolute neutrophil counts were low (<1 x 109/L with intermittent increases during sepsis. Human recombinant granulocyte colony-stimulating factor administered subcutaneously (10 µg/kg per day initially) resulted in an absolute neutrophil count of greater than 30 x109/L within 2 weeks. The dosage was lowered and the absolute neutrophil counts were maintained at 8 to 12 x 109/L with no further septic episodes. The human recombinant granulocyte colony-stimulating factor therapy was discontinued after 7 months, and the patient remained healthy with an absolute neutrophil count of greater than 2x109/L. Thus, treatment with human recombinant granulocyte colony-stimulating factor may be useful as a temporary measure for neonatal neutropenia associated with sepsis. A controlled, clinical trial is warranted.

(AJDC. 1991;145:808-812)



Author Affiliations

From the Departments of Pediatrics (Drs Roberts and Szelc) and Medicine (Drs Scates and Glaspy and Ms Boyd), UCLA School of Medicine, Los Angeles, Calif, and Amgen Inc, Thousand Oaks, Calif (Messrs Soderstrom and Davis).


Footnotes

Accepted for publication January 28, 1991.

Presented in part at the annual Society of Pediatric Research meeting, Anaheim, Calif, May 10, 1990.

Reprint requests to the Department of Pediatrics, 22-387 MDCC, UCLA Medical Center, Los Angeles, CA 90024 (Dr Roberts).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.